Explore
Validate
Learn2764
antibody from Cell Signaling Technology, Inc
Targeting: BCL2L1
Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 2764 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#2764, RRID:AB_2228008
- Product name
- Bcl-xL (54H6) Rabbit mAb
- Antibody type
- Monoclonal
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Rabbit
- Storage
- -20°C
Submitted references Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.
Jane EP, Premkumar DR, Pollack IF
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Molecular cancer therapeutics 2011 Jan;10(1):198-208
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M
PloS one 2011 Jan 31;6(1):e14640
PloS one 2011 Jan 31;6(1):e14640
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ
The Journal of biological chemistry 2009 Dec 4;284(49):34342-54
The Journal of biological chemistry 2009 Dec 4;284(49):34342-54
No comments: Submit comment
No validations: Submit validation data